低剖面Zenith Alpha腹主动脉覆膜支架的临床性能:ZEPHYR注册研究2年结果
ZEPHYR注册研究为医生发起的多中心、非随机、核心实验室控制的前瞻性注册研究,纳入347例非破裂腹主动脉瘤患者,评估低剖面Zenith Alpha腹主动脉覆膜支架的中期结局。2年治疗成功率为85.3%,免于二次干预率为86.9%,肢体并发症发生率令人担忧。
要点
- 2年治疗成功率为85.3%,免于二次干预率为86.9%。
- 二次干预的主要原因为肢体并发症。
- 2年免于肢体闭塞率(按患者计)为92.5%。
核心结论
- 虽然治疗成功率与其他市售覆膜支架相当,但2年时肢体并发症的发生率令人担忧。
- 应严格遵循制造商的说明书。
- 需要进一步研究以探究Zenith Alpha腹主动脉覆膜支架肢体并发症发生率增加的根本原因。
研究设计与样本
- ZEPHYR注册研究为医生发起的多中心、非随机、核心实验室控制的前瞻性注册研究。
- 纳入标准为非破裂腹主动脉瘤,最大直径≥50 mm或6个月内增大>5 mm,站点报告的肾下颈长度≥10 mm,并计划择期植入Zenith Alpha腹主动脉覆膜支架。
- 共纳入来自德国、比利时和荷兰14个中心的347例患者。
- 主要终点为治疗成功,定义为技术成功和临床成功。
- 技术成功定义为覆膜支架成功输送并部署在计划位置,无意外覆盖髂内动脉或肾动脉,且输送系统成功撤除。
主要发现
- 中位临床随访时间为743天(四分位距[IQR] 657,806),中位影像随访时间为725天(IQR 408,788)。
- 6个月、1年和2年治疗成功率分别为92.5%、90.4%和85.3%。
- 6个月、1年和2年免于二次干预率分别为94.3%、93.4%和86.9%。
- 二次干预的主要原因为肢体并发症。
- 6个月、1年和2年免于肢体闭塞率(按患者计)分别为97.2%、95.8%和92.5%。
临床怎么用
- 作者认为应严格遵循制造商的说明书。
- 作者建议需要进一步研究以探究Zenith Alpha腹主动脉覆膜支架肢体并发症发生率增加的根本原因。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The midterm outcomes of the low profile Zenith Alpha Abdominal Endovascular Graft from the ZEnith alPHa for aneurYsm Repair (ZEPHYR) registry are reported. METHODS: The ZEPHYR registry is a physician initiated, multicentre, non-randomised, core laboratory controlled, prospective registry. Inclusion criteria were patients with a non-ruptured abdominal aortic aneurysm with a maximum diameter ≥ 50 mm or enlargement > 5 mm within 6 months, with a site reported infrarenal neck length of ≥ 10 mm and with the intention to electively implant the Zenith Alpha abdominal endograft. Patients from 14 sites across Germany, Belgium, and the Netherlands were included. The primary endpoint was treatment success, defined as technical success and clinical success. Technical success was defined as successful delivery and deployment of the endograft in the planned position without unintentional coverage of internal iliac or renal arteries, with successful removal of the delivery system. Clinical success was defined as freedom from aneurysm sac expansion > 5 mm, type I or type III endoleaks, aneurysm rupture, stent graft migration > 10 mm, open conversion, and stent graft occlusion. RESULTS: Three hundred and forty-seven patients were included in the ZEPHYR registry. The median clinical follow up was 743 days (interquartile range [IQR] 657, 806) with a median imaging follow up of 725 days (IQR 408, 788). Treatment success at 6 months, 1, and 2 years was 92.5%, 90.4%, and 85.3%, respectively. Freedom from secondary intervention was 94.3%, 93.4%, and 86.9%, respectively. The predominant reason for secondary intervention was limb complications. Freedom from limb occlusion (per patient) at 6 months, 1, and 2 years was 97.2%, 95.8%, and 92.5%, respectively. Univariable and multivariable Cox regression analyses could not identify any independent predictor for limb complications. CONCLUSION: While treatment success is comparable with other commercially available grafts, the rate of limb complications at 2 years is of concern. The manufacturer's instructions for use should be followed closely. Further studies are necessary to investigate the root cause of the increased rate of limb complications with the Zenith Alpha Abdominal Endovascular Graft.
引用
- Hatzl J, van Basten Batenburg M, Yeung KK, et al. Clinical Performance of the Low Profile Zenith Alpha Abdominal Endovascular Graft: 2 Year Results from the ZEPHYR Registry. Eur J Vasc Endovasc Surg. 2024. PMID: 38490356. doi:10.1016/j.ejvs.2024.03.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。